SEARCH

SEARCH BY CITATION

References

  • 1
    Yap TA, Brunetto A, Pandha H, et al. Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs 2008; 17: 192535.
  • 2
    Prestwich RJ, Harrington KJ, Pandha HS, et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008; 8: 15818.
  • 3
    Seymour LW, Cawood R, Fisher KD. Cellular carriers or free viruses? Curr Opin Mol Ther 2008; 10: 3212.
  • 4
    Errington F, Steele L, Prestwich R, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008; 180: 601826.
  • 5
    Errington F, White CL, Twigger KR, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008; 15: 125770.
  • 6
    Prestwich RJ, Errington F, Ilett EJ, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008; 14: 735866.
  • 7
    White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (dearing type 3) during a phase I clinical trial. Gene Ther 2008; 15: 91120.
  • 8
    Prestwich RJ, Errington F, Steele LP, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009; 183: 431221.
  • 9
    Prestwich RJ, Ilett EJ, Errington F, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009; 15: 437481.
  • 10
    Steele L, Errington F, Prestwich R, et al. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is pkr/nf-kappab mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer 2011; 10: 20.
  • 11
    Stoeckel J, Hay JG. Drug evaluation: reolysin—wild-type reovirus as a cancer therapeutic. Curr Opin Mol Ther 2006; 8: 24960.
  • 12
    Harrington KJ, Vile RG, Melcher A, et al. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010; 21: 918.
  • 13
    Power AT, Bell JC. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 2008; 15: 7729.
  • 14
    Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: fed ex for cancer therapy. Mol Ther 2009; 17: 166776.
  • 15
    Nandan MO, Yang VW. Genetic and chemical models of colorectal cancer in mice. Curr Colorectal Cancer Rep 2010; 6: 5159.
  • 16
    Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696701.
  • 17
    Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 712737.
  • 18
    Errington F, Jones J, Merrick A, et al. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and t-cell priming. Gene Ther 2006; 13: 13849.
  • 19
    Barton ES, Forrest JC, Connolly JL, et al. Junction adhesion molecule is a receptor for reovirus. Cell 2001; 104: 44151.
  • 20
    Hewitt RE, McMarlin A, Kleiner D, et al. Validation of a model of colon cancer progression. J Pathol 2000; 192: 44654.
  • 21
    Clarke P, Tyler KL. Reovirus-induced apoptosis: a minireview. Apoptosis 2003; 8: 14150.
  • 22
    Qiao J, Kottke T, Willmon C, et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive t cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 2008; 14: 3744.
  • 23
    Ilett EJ, Prestwich RJ, Kottke T, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther 2009; 16: 68999.
  • 24
    Ilett EJ, Barcena M, Errington-Mais F, et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 2011; 17: 276776.
  • 25
    Andrews DM, Andoniou CE, Scalzo AA, et al. Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol 2005; 42: 54755.
  • 26
    Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of reolysin(r), a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2009; 28: 6429.
  • 27
    Burt BM, Plitas G, Zhao Z, et al. The lytic potential of human liver nk cells is restricted by their limited expression of inhibitory killer Ig-like receptors. J Immunol 2009; 183: 178996.
  • 28
    Li Z, Diehl AM. Innate immunity in the liver. Curr Opin Gastroenterol 2003; 19: 56571.
  • 29
    Donnelly OG, Errington-Mais F, Prestwich R, et al. Recent clinical experience with oncolytic viruses. Curr Pharm Biotechnol 2012; 13: 183441.
  • 30
    Adair RA, Roulstone V, Scott KJ, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012; 4: 138ra77.
  • 31
    Selb B, Weber B. A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods 1994; 47: 1525.
  • 32
    Comins C, Spicer J, Protheroe A, et al. Reo-10: a phase 1 study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010; 16: 556472.
  • 33
    Lopez-Nevot MA, Esteban F, Ferron A, et al. HLA class i gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59: 2216.